Inosi Therapeutics
- Biotech or pharma, therapeutic R&D
Inosi Therapeutics is developing first in class, novel mechanism of action, small molecule inhibitors of Insulin Regulated Aminopeptidase (IRAP), that have shown a striking ability to reverse established kidney and cardiac fibrosis and improve organ function in animal models of diabetes, aging, and other disease-associated fibrotic models.
Our lead IRAP inhibitor program is ready to start IND-enabling development, and we are also building a broader pipeline focused on aminopeptidase targets with strong therapeutic potential.
The MoA showing reversal of fibrosis provides an exciting and very differentiated opportunity in the fibrosis space, and we are seeking to engage with partners who have a strategic interest in novel therapeutics in renal and cardiometabolic indications with high unmet need.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}